---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-136384"
form_type: "8-K"
ticker: "LRMR"
cik: "0001374690"
company_name: "Larimar Therapeutics, Inc."
filed_at: "2024-12-16T23:59:59+00:00"
generated_at: "2026-05-29T02:50:09.729799+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Larimar reports positive OLE data: FXN up to 30% of healthy in buccal cells at Day 90; BLA filing targeted 2H 2025

## Summary
- Mean change from baseline of 1.32 pg/μg in buccal cells and 9.28 pg/μg in skin cells at Day 90.
- Tissue FXN increased from 15% to 30% of healthy volunteers in buccal cells and 16% to 72% in skin cells.
- Daily 25 mg nomlabofusp generally well tolerated; two SAEs resolved within 24 hours; 50 mg dose escalation initiated.
- BLA submission for potential accelerated approval targeted for 2H 2025; cash runway of $203.7M into Q2 2026.
- Early trends towards improvement in mFARS, ADL, and other clinical outcomes observed at Day 90.

## SEC filing metadata
- accession: 0000950170-24-136384
- form_type: 8-K
- ticker: LRMR
- cik: 0001374690
- company_name: Larimar Therapeutics, Inc.
- filed_at: 2024-12-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374690/000095017024136384/0000950170-24-136384-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374690/000095017024136384/lrmr-20241216.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-136384
- JSON: https://secwatch.observer/filing/0000950170-24-136384.json
- Plain text: https://secwatch.observer/filing/0000950170-24-136384.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.